The "2018 China Biopharma Industry International Investment Cooperation Conference" co-organized by Ministry of Commerce Investment Promotion Affairs Bureau , Bio Valley and Deloitte China was grandly held in Shanghai on April 1.
Relevant leaders of the Ministry of Commerce, the National Health Commission, the Ministry of Industry and Information Technology, the Ministry of Science and Technology, the National Medical Evaluation Center, together with experts and scholars in the field of scientific research and medical care, as well as investment experts and experts in the medical and health industry, gathered in Shanghai to discuss the application of information technology in the four prefaces of "artificial intelligence, blockchain, automation, and informatization", and jointly discuss the blueprint of the future smart biomedicine ecological industry chain. During this period, the "2017 China Pharmaceutical and Health Industry Investment Promotion Report" and the "2017 China Biopharmaceutical Industry Park White Paper" were released, and the best park award ceremony for the "2017 China Biopharmaceutical Park Selection" event was held. At the award ceremony of
, the Dongguan Cross-Strait Biotechnology Industry Cooperation Base located in Songshan Lake won the title of "China's Most Potential Biomedicine Park and China's Most Characteristic Biomedicine Park".
Biomedicine is a sunrise industry in the 21st century and has now become a new global economic growth point. As one of my country's seven strategic emerging industries, the development of the biopharmaceutical industry has received high attention from governments at all levels. Local governments have introduced a number of support policies and increased investment to promote park construction and industrial development in the biopharmaceutical field. There are nearly 100 cities involving biomedical bases in China and more than 300 biomedical parks involved in biomedical parks. Although the domestic biomedicine full industrial chain model is not yet mature and the review and approval system is still being improved and improved, there is broad prospects for the future. The park is the main carrier of the agglomeration of the biopharmaceutical industry. Since biomedicine is characterized by high technology, high investment, high risk and high returns, and is closely related to policy control and market resources, the unified planning and layout, policy construction, public platforms, guarantees and service systems of the park are crucial.
Dongguan established a cross-strait biotechnology industry cooperation base in 2012, with an investment of nearly 10 billion yuan and a planned land of more than 8,200 mu. It is clear that Songshan Lake is used as the core of the base to start the early development and construction, and a state-owned Dongguan Biotechnology Industry Development Co., Ltd. is established to lead the development, construction and operation management.
After the first five years of development, Songshan Lake Biobase has gathered more than 300 biotechnology companies including Dongyangguang Pharmaceutical, Sansheng Pharmaceutical, Shenzhen Anke, Shanghai Pharmaceutical, Boomuhua, Pumen Technology, Modern Dentistry, Feipeng Biology and Baihong Regenerative Medicine Industrial Park, and the industrial agglomeration trend in the fields of medical devices, biomedicine and health care products is obvious. On March 14, the Guangdong Provincial Food and Drug Administration disclosed that there were 92 quality credit Class A medical device manufacturers in 2017, ranking third in Dongguan, second only to Shenzhen and Guangzhou. At the same time, the base's industrial service system has been gradually established, with a number of biotechnology teaching and scientific research institutions, 9 major bioindustry public platforms, etc.
According to Song Tao, chairman of Dongguan Biotechnology Company, this year's government work report clearly states that the overall plan for Guangdong-Hong Kong-Macao Greater Bay Area will be issued and implemented this year. During the National "Two Sessions", Guangdong Province also further clarified that it will build an international first-class bay area and world-class urban agglomeration . This is an opportunity for the development of Dongguan’s biopharmaceutical industry! Next, on the basis of reporting to the municipal government to speed up the introduction of biotechnology industry policies, Dongguan Biotechnology Company will comprehensively promote the construction of bases and promote the development and growth of Dongguan's biopharmaceutical industry. First, strengthen the overall planning of the base and the construction of biotechnology industry carriers, develop theme boutique parks, and form distinctive industrial agglomerations. The second is to further carry out global investment promotion and introduce a number of advantageous enterprises and industry-leading projects. The third is to establish scientific research platforms such as the Biopharmaceutical Research Institute to strengthen technological research, introduce and implement global leading technologies and products. While strengthening and improving the public platform for the development of the bioindustry, we strive to cultivate excellent biopharmaceutical companies on their own in the near future. Fourth, establish a bioindustry fund to leverage more funds to participate in Dongguan's biotechnology industry construction and provide more financial support for corporate development.Fifth, build an interconnected ecosystem for the biological industry, establish an integrated industrial chain of R&D, production, service, sales, etc.; we hope to build an echelon for the development of Dongguan's biological industry, cultivate a number of high-quality projects, support a number of excellent enterprises, strengthen a number of leading enterprises, and cultivate and develop and strengthen the Dongguan biological industry as soon as possible.
[Writing] Huang Shaohong
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-